Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma

摘要: Study Type – Prognosis (cohort series) Level of Evidence 2b What's known on the subject? and What does study add? In literature, few studies have evaluated role tumour burden (TB) in metastatic real cell carcinoma (mRCC), even though it has been considered as important localized tumours. In patients TB is uncertain because was analyzed chemotherapy treated or using a partial evaluation TB. This study, first reports independent prognostic predictive mRCC with targeted agents prospective clinical trials. able to predict prognosis independently localization metastases class defined by MSKCC criteria, moreover strictly related patient's performance status. OBJECTIVE •  To investigate possible baseline terms progression-free survival (PFS) overall (OS), renal (mRCC). PATIENTS AND METHODS •  A homogenous group enrolled second-line trials post-cytokine treatment were selected for present analysis. •  The Response Evaluation Criteria Solid Tumors (the sum longest unidimensional diameter each target lesion) used assess TB. •  The PFS OS rates estimated Kaplan–Meier method compared across groups log-rank test. •  The association between Cox proportional hazards model. Multivariable analyses adjusted other variables: Memorial Sloan Kettering Cancer Centre (MSKCC) risk treatment. RESULTS •  A total 124 included final analysis. Of these, 66% received sorafenib sunitinib 34% placebo. The median follow-up 80.1 month. •  TB directly these associations remained significant after adjusting modified treatment,. •  Each 1-cm increase increased progression 4.5% (hazard ratio [HR]: 1.05; 95% confidence interval [CI] 1.02–1.07; P < 0.001) death 5% (HR: CI 1.03–1.08; 0.001). CONCLUSIONS •  TB easy calculate from standard computed tomography significantly relates mRCC. •  We report time multivariate analysis. •  We believe that this information could be translated into practice.